Comparison · NCT02481830-sae
Group A vs Group B: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A vs Group B: serious adverse events. Trial comparisons, record NCT02481830-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02481830-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.649 | 0.592 | 0.702 | wilson | |
| Risk in group 2 | 0.645 | 0.586 | 0.7 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00365 | -0.0759 | 0.0834 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.889 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.715 | 1.44 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Group A than on Group B | 274 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A | Nivolumab 240mg IV on Day 1 of a 14-day cycle | 183 | 282 | EG000 |
| Group 2 | Group B | Chemotherapy (Topotecan 1.5 mg/m\^2 IV or 2.3 mg/m\^2 oral once daily on Days 1 to 5 of a 21-day cycle / Amrubicin 40 mg/m\^2 IV once daily on Days 1 to 3 of a 21-day cycle) | 171 | 265 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
SAEs and Other AEs are assessed from first dose to 100 days post last dose (Up to approximately 72 months). Participants were assessed for all-cause mortality from their randomization to study completion (Up to approximately 80 months).
Source ClinicalTrials.gov
Trial
- Title
- Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
- NCT number
- NCT02481830
- Phases
- PHASE3
- Conditions
- Lung Cancer
- Interventions
- Nivolumab, Topotecan, Amrubicin
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2020-01-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02481830?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02481830-sae